BIO-RAD LABORATORIES -CL B (BIO.B) Fundamental Analysis & Valuation

NYSE:BIO.B • US0905721082

Current stock price

268.55 USD
+0.06 (+0.02%)
Last:

This BIO.B fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. BIO.B Profitability Analysis

1.1 Basic Checks

  • BIO.B had positive earnings in the past year.
  • In the past year BIO.B had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: BIO.B reported negative net income in multiple years.
  • BIO.B had a positive operating cash flow in each of the past 5 years.
BIO.B Yearly Net Income VS EBIT VS OCF VS FCFBIO.B Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B -2B 4B

1.2 Ratios

  • BIO.B has a Return On Assets of 7.18%. This is amongst the best in the industry. BIO.B outperforms 84.21% of its industry peers.
  • BIO.B has a Return On Equity of 10.20%. This is in the better half of the industry: BIO.B outperforms 78.95% of its industry peers.
  • BIO.B's Return On Invested Capital of 2.02% is fine compared to the rest of the industry. BIO.B outperforms 61.40% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for BIO.B is significantly below the industry average of 11.85%.
Industry RankSector Rank
ROA 7.18%
ROE 10.2%
ROIC 2.02%
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
BIO.B Yearly ROA, ROE, ROICBIO.B Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20

1.3 Margins

  • BIO.B has a better Profit Margin (29.42%) than 96.49% of its industry peers.
  • BIO.B's Profit Margin has declined in the last couple of years.
  • The Operating Margin of BIO.B (10.30%) is better than 70.18% of its industry peers.
  • BIO.B's Operating Margin has declined in the last couple of years.
  • BIO.B has a Gross Margin of 52.01%. This is in the better half of the industry: BIO.B outperforms 61.40% of its industry peers.
  • In the last couple of years the Gross Margin of BIO.B has declined.
Industry RankSector Rank
OM 10.3%
PM (TTM) 29.42%
GM 52.01%
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
BIO.B Yearly Profit, Operating, Gross MarginsBIO.B Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. BIO.B Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO.B is destroying value.
  • The number of shares outstanding for BIO.B has been reduced compared to 1 year ago.
  • BIO.B has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for BIO.B has been reduced compared to a year ago.
BIO.B Yearly Shares OutstandingBIO.B Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
BIO.B Yearly Total Debt VS Total AssetsBIO.B Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.2 Solvency

  • BIO.B has an Altman-Z score of 3.07. This indicates that BIO.B is financially healthy and has little risk of bankruptcy at the moment.
  • BIO.B has a Altman-Z score of 3.07. This is in the better half of the industry: BIO.B outperforms 68.42% of its industry peers.
  • BIO.B has a debt to FCF ratio of 3.21. This is a good value and a sign of high solvency as BIO.B would need 3.21 years to pay back of all of its debts.
  • The Debt to FCF ratio of BIO.B (3.21) is better than 82.46% of its industry peers.
  • BIO.B has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
  • BIO.B has a Debt to Equity ratio of 0.16. This is comparable to the rest of the industry: BIO.B outperforms 56.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 3.21
Altman-Z 3.07
ROIC/WACC0.19
WACC10.6%
BIO.B Yearly LT Debt VS Equity VS FCFBIO.B Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B 8B 10B

2.3 Liquidity

  • BIO.B has a Current Ratio of 5.62. This indicates that BIO.B is financially healthy and has no problem in meeting its short term obligations.
  • BIO.B's Current ratio of 5.62 is amongst the best of the industry. BIO.B outperforms 82.46% of its industry peers.
  • A Quick Ratio of 4.19 indicates that BIO.B has no problem at all paying its short term obligations.
  • BIO.B has a Quick ratio of 4.19. This is in the better half of the industry: BIO.B outperforms 75.44% of its industry peers.
Industry RankSector Rank
Current Ratio 5.62
Quick Ratio 4.19
BIO.B Yearly Current Assets VS Current LiabilitesBIO.B Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BIO.B Growth Analysis

3.1 Past

  • The earnings per share for BIO.B have decreased by -3.78% in the last year.
  • The Earnings Per Share has been decreasing by -1.19% on average over the past years.
  • The Revenue has been growing slightly by 0.65% in the past year.
  • BIO.B shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.29% yearly.
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%

3.2 Future

  • BIO.B is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.58% yearly.
  • BIO.B is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.54% yearly.
EPS Next Y4.57%
EPS Next 2Y7.58%
EPS Next 3Y7.11%
EPS Next 5Y0.58%
Revenue Next Year1.81%
Revenue Next 2Y2.49%
Revenue Next 3Y2.54%
Revenue Next 5Y2.54%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BIO.B Yearly Revenue VS EstimatesBIO.B Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
BIO.B Yearly EPS VS EstimatesBIO.B Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

3

4. BIO.B Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 27.07, the valuation of BIO.B can be described as expensive.
  • BIO.B's Price/Earnings ratio is a bit cheaper when compared to the industry. BIO.B is cheaper than 68.42% of the companies in the same industry.
  • BIO.B is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 25.71, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 25.89, which means the current valuation is very expensive for BIO.B.
  • BIO.B's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BIO.B is cheaper than 63.16% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of BIO.B to the average of the S&P500 Index (23.83), we can say BIO.B is valued inline with the index average.
Industry RankSector Rank
PE 27.07
Fwd PE 25.89
BIO.B Price Earnings VS Forward Price EarningsBIO.B Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, BIO.B is valued a bit cheaper than 77.19% of the companies in the same industry.
Industry RankSector Rank
P/FCF 19.35
EV/EBITDA N/A
BIO.B Per share dataBIO.B EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150 200 250

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BIO.B does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)5.92
PEG (5Y)N/A
EPS Next 2Y7.58%
EPS Next 3Y7.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BIO.B Dividend Analysis

5.1 Amount

  • BIO.B does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIO.B Fundamentals: All Metrics, Ratios and Statistics

BIO-RAD LABORATORIES -CL B

NYSE:BIO.B (3/12/2026, 8:25:01 PM)

268.55

+0.06 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)04-29
Inst Owners90.44%
Inst Owner Change-2.11%
Ins Owners8.17%
Ins Owner ChangeN/A
Market Cap7.25B
Revenue(TTM)2.58B
Net Income(TTM)759.90M
Analysts76
Price Target342.51 (27.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.88%
Min EPS beat(2)-7.97%
Max EPS beat(2)15.74%
EPS beat(4)3
Avg EPS beat(4)23.95%
Min EPS beat(4)-7.97%
Max EPS beat(4)49.07%
EPS beat(8)7
Avg EPS beat(8)28.31%
EPS beat(12)9
Avg EPS beat(12)18.55%
EPS beat(16)11
Avg EPS beat(16)17.09%
Revenue beat(2)0
Avg Revenue beat(2)-0.54%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)-0.35%
Revenue beat(4)2
Avg Revenue beat(4)1.22%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)0.02%
Revenue beat(12)3
Avg Revenue beat(12)-1.41%
Revenue beat(16)5
Avg Revenue beat(16)-1.09%
PT rev (1m)-4.65%
PT rev (3m)-5.79%
EPS NQ rev (1m)-26.04%
EPS NQ rev (3m)-26.33%
EPS NY rev (1m)1.2%
EPS NY rev (3m)-0.1%
Revenue NQ rev (1m)-2.1%
Revenue NQ rev (3m)-2.22%
Revenue NY rev (1m)-0.56%
Revenue NY rev (3m)-0.9%
Valuation
Industry RankSector Rank
PE 27.07
Fwd PE 25.89
P/S 2.81
P/FCF 19.35
P/OCF 13.62
P/B 0.97
P/tB 1.08
EV/EBITDA N/A
EPS(TTM)9.92
EY3.69%
EPS(NY)10.37
Fwd EY3.86%
FCF(TTM)13.88
FCFY5.17%
OCF(TTM)19.72
OCFY7.34%
SpS95.71
BVpS276.16
TBVpS248.22
PEG (NY)5.92
PEG (5Y)N/A
Graham Number248.27
Profitability
Industry RankSector Rank
ROA 7.18%
ROE 10.2%
ROCE 2.65%
ROIC 2.02%
ROICexc 2.38%
ROICexgc 2.62%
OM 10.3%
PM (TTM) 29.42%
GM 52.01%
FCFM 14.5%
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
ROICexc(3y)2.76%
ROICexc(5y)2.85%
ROICexgc(3y)3.02%
ROICexgc(5y)3.08%
ROCE(3y)3.04%
ROCE(5y)3.23%
ROICexgc growth 3Y-9.86%
ROICexgc growth 5Y-2.45%
ROICexc growth 3Y-10.58%
ROICexc growth 5Y-3.39%
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
F-Score5
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 3.21
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 6.1%
Interest Coverage -5.71
Cash Conversion N/A
Profit Quality 49.3%
Current Ratio 5.62
Quick Ratio 4.19
Altman-Z 3.07
F-Score5
WACC10.6%
ROIC/WACC0.19
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)6.44%
Cap/Sales(5y)5.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
EPS Next Y4.57%
EPS Next 2Y7.58%
EPS Next 3Y7.11%
EPS Next 5Y0.58%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%
Revenue Next Year1.81%
Revenue Next 2Y2.49%
Revenue Next 3Y2.54%
Revenue Next 5Y2.54%
EBIT growth 1Y-12.48%
EBIT growth 3Y-18.24%
EBIT growth 5Y-8.78%
EBIT Next Year46.85%
EBIT Next 3Y17.21%
EBIT Next 5Y9.79%
FCF growth 1Y40.72%
FCF growth 3Y66.2%
FCF growth 5Y-4.69%
OCF growth 1Y16.92%
OCF growth 3Y39.89%
OCF growth 5Y-1.87%

BIO-RAD LABORATORIES -CL B / BIO.B Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BIO-RAD LABORATORIES -CL B (BIO.B) stock?

ChartMill assigns a fundamental rating of 5 / 10 to BIO.B.


Can you provide the valuation status for BIO-RAD LABORATORIES -CL B?

ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES -CL B (BIO.B). This can be considered as Overvalued.


How profitable is BIO-RAD LABORATORIES -CL B (BIO.B) stock?

BIO-RAD LABORATORIES -CL B (BIO.B) has a profitability rating of 5 / 10.


How financially healthy is BIO-RAD LABORATORIES -CL B?

The financial health rating of BIO-RAD LABORATORIES -CL B (BIO.B) is 8 / 10.